Who knows, Tony has a servere aversion to PR.He might be a award winning scientist but as CEO of a public listed company he has no respect for his shareholders investment.He lost me, post FDA approval.
Would be different if he had some sales on the board or maybe a profit figure.
The boys bailed out at $3.20 and watched the shareprice plumment to $2.25 and still refused to give us a little publicity with the approval.
Maybe the lads over at PXS should buy him lunch.
Regards,
CST Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held